<DOC>
	<DOCNO>NCT01907100</DOCNO>
	<brief_summary>This phase II/III confirmatory study design evaluate safety efficacy nintedanib ( BIBF 1120 ) combination + ( pemetrexed / cisplatin ) follow nintedanib ( BIBF 1120 ) versus placebo + pemetrexed / cisplatin follow placebo treatment patient unresectable malignant pleural mesothelioma .</brief_summary>
	<brief_title>Nintedanib ( BIBF 1120 ) Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm malignant pleural mesothelioma ( MPM ) ( Epithelioid biphasic subtype Phase II patient ; epithelioid subtype Phase III patient ) Life expectancy least 3 month opinion investigator Eastern Cooperative Oncology Group ( ECOG ) score 0 1 Measurable disease accord modify RECIST ( Response Evaluation Criteria In Solid Tumours ) criterion Exclusion criterion : Previous systemic chemotherapy MPM Prior treatment nintedanib prior line therapy Phase II patient sarcomatoid subtype MPM Phase III patient biphasic sarcomatoid subtype MPM Patients symptomatic neuropathy Radiotherapy ( except extremity ) within 3 month prior baseline image Active brain metastasis ( e.g . stable &lt; 4 week ) Radiographic evidence cavitary necrotic tumour local invasion major blood vessel MPM Significant cardiovascular disease Inadequate hematologic , renal , hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>